Clinical Trial Finder

DISEASE CHARACTERISTICS:

• - One of the following histologically confirmed diseases for which no curative surgical, radiotherapy, or chemotherapy programs are available and standard therapy offers, at best, a modest clinical benefit.

• - Solid tumors.

• - Gliomas.

• - Non-Hodgkin's lymphoma.

• - Primary and metastatic CNS malignancies are eligible.

• - Evaluable or measurable disease.

• - CD34 count at least 2.0 cells/μL.

• - No bone marrow involvement.

• - Histologically negative bone marrow biopsy.

PATIENT CHARACTERISTICS: Age:

• - 18 to 70.

Performance status:

• - ECOG 0-2.

Life expectancy:

• - At least 12 weeks.

Hematopoietic:

• - Absolute neutrophil count at least 1,500/mm^3.

• - Platelet count at least 100,000/mm^3.

• - Hemoglobin at least 8.5 g/dL.

Hepatic:

• - Bilirubin no greater than 1.5 mg/dL.

• - AST and ALT less than 2.5 times normal.

• - Prothrombin time less than 1.2 times normal.

Renal:

• - Creatinine no greater than 2.0 mg/dL.

Cardiovascular:

• - No acute cardiac disease by EKG.

Pulmonary:

• - No symptomatic pulmonary disease.

Other:

• - HIV negative.

• - No other severe comorbid conditions.

• - Not pregnant or nursing.

• - Fertile patients must use effective contraception during and for 2 months after study completion.

PRIOR CONCURRENT THERAPY: Biologic therapy:

• - See Chemotherapy.

• - No prior hematopoietic stem cell transplantation.

Chemotherapy:

• - No prior high-dose chemotherapy.

• - Prior adjuvant chemotherapy allowed.

Endocrine therapy:

• - Not specified.

Radiotherapy:

• - No prior radiotherapy to 25% or more of bone marrow.

Surgery:

• - Not specified.

Other: - At least 4 weeks since prior myelosuppressive therapy

OBJECTIVES:

• - Evaluate the feasibility of introducing and expressing mutant MGMT-G156A cDNA in hematopoietic progenitors taken from patients with advanced solid tumors (including gliomas) or non-Hodgkin's lymphoma using a safety modified retroviral vector MFG.

• - Determine the toxicity associated with reinfusion of ex vivo-transduced hematopoietic stem cells into these patients, including the detection of replication competent retrovirus.

• - Evaluate the feasibility of identifying mutant MGMT-G156A-transduced and O6-benzylguanine (BG)- and temzolomide-resistant hematopoietic and stromal progenitors from the bone marrow of these patients.

• - Evaluate the feasibility of in vivo enrichment of the transduced hematopoietic progenitors in patients treated with BG and temzolomide.

• - Evaluate the toxicity of this regimen in these patients.

• - Determine the antitumor effect of this regimen in these patients.

OUTLINE: This is a dose-escalation study of CD34 stem cells and carmustine. After a negative bone marrow sampling, patients receive sargramostim (GM-CSF) and filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days). Peripheral blood progenitor cells are collected 24 hours after the last dose of growth factor injection on day 5 and also on day 6, if necessary. The CD34 positive stem cells are then infected by the retroviral mutant MGMT-G156A ex vivo. Patients receive O6-benzylguanine (BG) IV over 1 hour followed by carmustine IV over 1 hour every 6 weeks for 5 courses, assuming recovery of peripheral blood counts. Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour followed by temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity provided other phase II studies indicate the safety of more than 5 courses. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine. Patients are followed monthly for 2 months, every 4 months for 8 months, and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study.